{
    "nct_id": "NCT03200340",
    "official_title": "Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate EC-18 for Oral Mucositis in Patients With Concomitant Chemoirradiation for Cancers of the Mouth, Oropharynx, Hypopharynx and Nasopharynx",
    "inclusion_criteria": "* Signed informed consent\n* Male or female age 18 years or older\n* Pathologically confirmed diagnosis of squamous cell carcinoma of the mouth, oropharynx, hypopharynx or nasopharynx\n* Planned to receive IMRT with daily fractions of 2.0 Gy to 2.2 Gy to a cumulative dose of at least 60 Gy and a maximum of 72 Gy\n* Radiation fields to include at least two mucositis sites at risk (buccal mucosa, floor of mouth, ventral and lateral tongue, soft palate) in which both sites receive a minimum cumulative dose of 55 Gy\n* Planned to receive concomitant single agent chemotherapy with cisplatin given either weekly or tri-weekly\n* Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1\n* Screening Laboratory Values Hemoglobin ≥ 9g/dL White blood cell count ≥ 3,500 cells/mm3 Absolute neutrophil count ≥ 1,500 cells/mm3 Total bilirubin ≤ 2 times upper limit of normal Serum AST and ALT ≤ 2.5 times upper limit of normal Serum creatinine concentration ≤ 2mg/mL Pregnancy test: negative for females of childbearing potential\n* Subjects of childbearing potential must consent to utilize a medically accepted means of contraception throughout the active dosing period with study medication and for a minimum of 30 days following the administration of the last dose of study medication.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Unable to provide informed consent or, in the opinion of the Principal Investigator, comply with the protocol.\n\n  * Prior radiation therapy to the head and neck\n  * Metastatic disease\n  * Presence of active infectious disease excluding oral candidiasis\n  * Presence of oral mucositis or any oral lesion that would confound the assessment of oral mucositis\n  * Active systemic disease or condition known to impact the risk or course of oral mucositis including chronic immunosuppression and known seropositivity for HIV\n  * Use of any investigational agent within 30 days of the first radiation dose\n  * Active alcohol abuse syndrome\n  * Subjects with a history of hepatitis of any etiology or hepatic insufficiency\n  * Pregnant or nursing at the time of signing informed consent\n  * Known sensitivity to any study medication\n  * Unwilling or unable to complete study diary\n  * Any other condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the protocol",
    "miscellaneous_criteria": ""
}